Condition: Hematologic Malignancy · Sponsor: Assistance Publique - Hôpitaux de Paris
This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.
This description comes directly from the study's public registry record.
Olivier HERMINE, PhD & MD · +33 144495282 · olivier.hermine@aphp.fr
Nelly Briand, PhD · 01 44 38 18 62 · nelly.briand@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Saint Louis | Paris, France | Recruiting |
| Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux | Pessac, France | Recruiting |
| IUCT Oncopole Toulouse | Toulouse, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Not Yet Recruiting |
| Hematology department / Necker Children's Hospital | Paris, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04707300